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OBJECTIVES This study evaluated the role of clinical rescreening of family members at risk for familial
dilated cardiomyopathy (FDC).
BACKGROUND Familial dilated cardiomyopathy is a genetic cardiomyopathy that usually is transmitted in an
autosomal dominant pattern and may underlie from one-quarter to one-half of idiopathic
dilated cardiomyopathy (IDC) diagnoses. Thus, FDC may present with advanced heart
failure (HF) or sudden cardiac death (SCD). Because FDC may respond to medical
intervention, we have previously recommended that screening of first-degree relatives
(parents, siblings, children) of patients diagnosed with IDC be undertaken to rule out FDC,
and that with a diagnosis of FDC in the kindred, unaffected but at-risk family members be
rescreened every three to five years.
METHODS Follow-up screening (history, examination, electrocardiogram, echocardiography) of a large
family with FDC was performed six years after initial screening.
RESULTS Of 68 family members who underwent rescreening, two (one with left ventricular enlarge-
ment only, one with a left bundle branch block) presented with advanced HF and SCD,
respectively. Two additional subjects, asymptomatic at initial screening, were also affected
with FDC at follow-up.
CONCLUSIONS Considerable vigilance for disease presentation and progression is indicated in at-risk
members of a kindred with FDC, especially those with incipient FDC. (J Am Coll Cardiol
2002;39:1503–7) © 2002 by the American College of Cardiology Foundation
Dilated cardiomyopathy (DCM), characterized by ventric-
ular dilation and impaired contractility, frequently presents
with heart failure (HF) or sudden cardiac death (SCD), and
causes considerable morbidity and mortality. Idiopathic
dilated cardiomyopathy (IDC) is DCM after identifiable
causes have been excluded. Familial dilated cardiomyopathy
(FDC) is defined as DCM in two or more closely related
family members who otherwise meet diagnostic criteria for
IDC. Until recently, the genetic transmission of DCM was
thought to be uncommon, but at least 20% of subjects with
IDC have first-degree family members who meet rigorous
diagnostic criteria for IDC (1). With less rigorous criteria,
35% to 48% of patients with IDC have been suggested to
have FDC (2,3), which is transmitted in an autosomal
dominant (AD) pattern in 90% of families studied (2–4).
Considerable evidence now supports a genetic basis for
FDC, with eight different autosomal genes and eight
additional FDC chromosomal loci implicated (Table 1).
When DCM is discovered, a thorough family history in
at least first- and second-degree relatives should be obtained
(heart failure, DCM, SCD, arrhythmia, stroke, etc.) to
assess for FDC. Because the family history is much less
sensitive than echocardiographic screening of relatives (1),
and because FDC usually follows an AD inheritance pat-
tern, clinical screening of first-degree relatives (parents,
siblings, children) by history, examination, electrocardio-
gram (ECG), and echocardiography has been recom-
mended (5). However, both the age of onset and clinical
presentation of FDC can be highly variable even within the
same family. For these reasons, the rescreening of at-risk
relatives was proposed to be undertaken every three to five
years (5).
We now report the results of clinical rescreening in a large
family with FDC six years after initial screening. In this
family we have excluded a mutation in LMNA, the gene that
encodes lamin A/C and the most common FDC disease
gene to date (6–10), as well as linkage to loci of other
known FDC disease genes and other previously reported
FDC loci (11–26) (Table 1) (Hershberger and Jakobs, data
not shown). Hence, both the screening and the detection of
FDC in this study were not aided by genotypic data but
were based only on clinical (phenotypic) data, a situation
that parallels the issues of FDC in clinical practice. We
present these observations to add further support to the
rescreening of at-risk members of other FDC kindreds.
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METHODS
After informed consent was obtained, 107 subjects in a
family with FDC underwent initial clinical screening in
1994 and 1995, as previously reported (FDC-1, in Crispell
et al. [5]). Follow-up clinical screening (medical history, a
physical examination, ECG and a two-dimensional and
M-mode echocardiogram) was offered to all family mem-
bers in 2000 and 2001. For this study, left ventricular
enlargement (LVE) was defined as a left ventricular end-
diastolic dimension (LVEDD) the 95th percentile of a
gender- and height-matched Framingham population (27);
DCM was defined as LVE with systolic dysfunction (LVEF
[left ventricular ejection fraction] 0.50). The diagnosis of
FDC was assigned with systolic dysfunction, DCM, or
LVE 97.5th percentile (28), after other possible con-
founding factors had been excluded (5,28).
RESULTS
Demographic data of the 107 subjects screened in 1994 and
1995 and the 68 rescreened in 2000 and 2001 are shown in
Table 2. Subjects with the affected phenotype and their
first-degree relatives are shown in an abbreviated pedigree
(Fig. 1) from one previously published (5). Of the eight
subjects who were assigned affected status at baseline
screening during 1994 and 1995, five (subjects III-1, III-17,
III-20, IV-12, V-3) again met criteria for affected status at
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AD  autosomal dominant
DCM  dilated cardiomyopathy
ECG  electrocardiogram
FDC  familial dilated cardiomyopathy
HF  heart failure
IDC  idiopathic dilated cardiomyopathy
LBBB  left bundle branch block
LVE  left ventricular enlargement
LVEDD  left ventricular end-diastolic dimension
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
SCD  sudden cardiac death
Table 1. Autosomal Dominant FDC Disease Genes and/or Loci
Locus Gene* Protein Comments Reference
Dilated cardiomyopathy
phenotype
9q13–q22 Italian family with DCM (11)
10q21–q23 8 of 12 affected with MVP (12)
15q14 ACTC Actin Missense mutations in two small, unrelated American families (13)
2q35 DES Desmin (14)
6q23–24 2 families with DCM and sensorineural hearing loss (15)
5q33–34 SGCD -sarcoglycan 1 small family and 2 other sporadic, de novo mutations (16)
14q12 MYH7 -myosin heavy chain 2 of 20 families; wide age of onset, prominent DCM (17)
1q32 TNNT Troponin T 3 families (2 reports) with identical 3 basepair inframe dropout;
3rd large family; all with early onset, aggressive disease
(17–19)
6q12–16 French family, highly variable penentrance (20)
15q22.1 TPM1 -tropomyosin 2 small unrelated families, highly variable onset (21)
2q31 TTN Titin 2 unrelated families with DCM (22)
Conduction system disease
with DCM
1p1–1q1 Very large Ohio State pedigree; 23 with AVB, 16 pacemakers (23)
3p22–25 Utah family with SA block, atrial arrthythmias; late LVE (24)
6q22–23 9 of 25 affected with pacemakers; minimal LVE; some MD (25)
2q14–q22 German family, heart block, later DCM; SCD, 5/6 with ICDs (26)
1q21.2–.3 LMNA Lamin A/C 10 families (5 reports); prominent AV block, pacemakers; later
DCM with heart failure; occasional MD
(6–10)
*Gene abbreviations from OMIM (http://www.ncbi.nlm.nih.gov/Omim/).
AVB  atrioventricular block; ICD  implantable cardiac defibrillator; MD  muscular dystrophy; MVP  mitral valve prolapse; SA  sinoatrial; SCD  sudden cardiac
death.
Table 2. Characteristics of Subjects Screened
1994–1995 2000–2001
Total living 158 181
Total screened 107 68
Children (16 yrs) (%) 46 (43.0) 20 (29.4)
Adults (%) 61 (57.0) 48 (70.6)
Age at screening (yrs) 23 27.7
Median (range) (1–65) (6–71)
Gender
Male (%) 50 (46.7) 27 (39.7)
Female (%) 57 (53.2) 41 (60.3)
Smoker 35 (32.7) 21 (30.9)
Former (%) 8 (7.5) 8 (11.8)
Current (%) 27 (25.2) 13 (19.1)
Medical history
Hypertension 3 (2.8) 3 (4.4)
Diabetes 3 (2.8) 5 (7.4)
Coronary artery disease 1 (0.9) 2 (2.9)
BSA (m2), median 1.75 1.9
(range) (0.47–2.54) (0.85–2.57)
BMI (kg/m2), median 25.1 28.4
(range) (12.6–52.9) (14.9–46.1)
BMI  body mass index; BSA  body surface area.
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rescreening, and three (subjects III-18, IV-1, IV-8) were
not available for rescreening; one (subject IV-3) had base-
line screening in 2000 (Table 3).
Two subjects, both asymptomatic at initial screening, had
developed advanced HF. At initial screening, subject IV-2
(Table 3, Fig. 1) had LVE without systolic dysfunction and
a normal ECG. Six years later she presented with decom-
pensated heart failure and required hospitalization. She was
noted to have a first-degree atrioventricular block and a left
bundle branch block (LBBB), further LVE and marked
systolic dysfunction (Table 3); coronary angiography was
normal. She was treated with diuretics, angiotensin-
converting enzyme (ACE) inhibitors and beta-blockers and
improved to New York Heart Association (NYHA) func-
tional class III. One year later, she showed further improve-
ment to a NYHA functional class II, her LVEDD de-
creased to 58 mm, and her LVEF improved to 0.40. The
second subject (III-9) (Table 3, Fig. 1), asymptomatic with
a LBBB on initial screening, presented six years later with
SCD. She was successfully resuscitated but suffered chronic
neurologic impairment. Comprehensive cardiovascular eval-
uation demonstrated normal coronary arteries, LVE and
marked systolic dysfunction (Table 3). She was treated with
conventional medical therapy.
A third subject (III-5), without LVE and intact systolic
function at our initial screening, developed criteria for
DCM at rescreening (Table 3). A fourth subject (III-7)
developed systolic dysfunction (Table 3).
DISCUSSION
Central findings. This work emphasizes that considerable
vigilance for disease presentation and progression is indi-
cated in at-risk members of a kindred with FDC. Two
subjects presented with advanced disease, SCD with resid-
ual neurologic injury (III-9) and decompensated HF (IV-2),
whereas six years previously both subjects were observed to
have cardiovascular abnormalities (LBBB and LVE, respec-
tively), but neither met usual criteria for DCM, and both
were asymptomatic. These observations also reemphasize
the need for cardiovascular specialists to assess genetic risk
for DCM, and to integrate family history data into diag-
nostic and therapeutic care plans of individual patients.
Screening recommendations. As previously recom-
mended (5), the rescreening of first-degree relatives of
subjects with known or suspected DCM every three to five
years will likely yield the greatest benefit (5). For example,
the SCD and new diagnosis of DCM (in subject III-9)
suggested that screening of her siblings and children was
indicated; indeed, two siblings (III-5, III-7) were discovered
to have disease not apparent at initial screening.
Key disease indicators. Left ventricular enlargement may
be a key indicator of disease (1,2,11). Michels et al. (1)
suggested that asymptomatic LVE may represent the earli-
est stage of FDC. In a linkage pedigree, Krajinovic et al.
(11) observed that family members with isolated LVE
carried the disease genotype. In a prospective follow-up
study of asymptomatic family members, 27% of those with
Figure 1. Pedigree including subjects with the affected phenotype and their first-degree relatives. Squares  males; circles  females; fully filled
symbols  affected status at baseline screening; half-filled symbols  a change to affected status based on follow-up screening, 2000 to 2001; N 
unaffected status; ?  unknown status; blank symbol  that the subject was not screened.
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LVE developed FDC over a period of 39  14 months (2).
In our study, we have observed the development of DCM in
a subject (IV-2) who had isolated LVE at initial screening.
Therefore, we suggest that subjects with newly identified
LVE in an FDC kindred warrant ongoing medical surveil-
lance for symptomatic disease (examination, ECG and
echocardiography) every one to three years. Whether con-
duction system disease is a key disease indicator is more
difficult to assess, but based on our experience, a LBBB in a
subject at risk (IV-9) may be a harbinger of further disease
and deserves close follow-up.
Medical treatment. For subjects diagnosed with FDC, we
have proposed generic treatment with ACE inhibitors
and/or beta-blockers (5), based on current American Col-
lege of Cardiology/American Heart Association guidelines
for patients with IDC and asymptomatic LVE, or IDC and
symptomatic heart failure (29).
Counseling. Family members should be counseled that: 1)
FDC has an unpredictable clinical course and an age-
dependent penetrance, and that normal screening results do
not exclude the possibility of developing future disease; 2)
symptoms may be highly variable and result from left
ventricular dysfunction and HF, or from symptomatic
arrhythmias (presyncope, syncope or SCD); 3) new cardio-
vascular symptoms should prompt evaluation by an in-
formed physician; 4) for AD FDC, affected subjects should
be informed that their children have a 50% probability of
inheriting the disease gene; and 5) for more specific ques-
tions pertaining to the clinical or genetic aspects of FDC,
family members may be referred to a cardiovascular special-
ist with expertise in genetic cardiomyopathies, a genetic
counselor or a geneticist (30).
Study limitations. The multiple FDC disease genes and
chromosomal loci, indicating substantial genetic heteroge-
neity, raise doubt about whether these clinical recommen-
dations based on one family can be generalized to all
instances of FDC. However, FDC (like IDC or ischemic
cardiomyopathy) usually responds to conventional medical
therapy once signs and symptoms are present. Also, these
generic screening recommendations may be tailored to a
specific kindred (e.g., to screen younger family members in
a kindred with a much earlier age of onset, etc.).
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Table 3. Clinical Characteristics of Subjects With Affected Phenotype
Pedigree
No.
Age at
Screenings
(yr)/Gender
LVEDD, mm
(Percentile)
Ejection
Fraction
(%)
DCM
(Y/N)
ECG
Abnormalities Comments
III-1 61/F 70 (99) 25 Y LBBB IDC diagnosed at 49 years; NYHA class III
68/F 67 (99) 15 Y LBBB, frequent PVCs
III-5 52/F 48 60 N none DCM diagnosed at rescreening, 58 years
58/F 51 (95) 45 Y none
III-7 49/M 50 60 N none
55/M 52 45 N none Normal coronary angiography
III-9 39/F 48 54 N LBBB Sudden cardiac death at 45 years; NYHA class III
45/F 62 (99) 14 Y LBBB
III-17 47/F 56 (99) 60 N 1st deg AVB
54/F 42 58 N 1st deg AVB
III-18 44/M 60 (99) 40 Y Bigeminy NYHA class I at initial screening; not rescreened
N/A N/A N/A N/A
III-20 60/M 71 (99) 45 Y NSST DCM diagnosed at 58 years (NYHA class II); now
NYHA class III65/M 60 (99) 25 Y NSST
IV-1 45/F 58 (99) 45 Y none DCM diagnosed at screening, 45 years; not rescreened
N/A N/A N/A N/A
IV-2 43/F 60 (99) 59 N none DCM diagnosed at 49 years (NYHA class III); now
NYHA class II49/F 63 (99) 15 Y LBBB, 1st deg AVB
IV-3 N/A N/A N/A N/A Baseline screening conducted in 2000
47/F 62 (99) 55 N none
IV-8 40/F 55 (99) 60 N none
N/A N/A N N/A Not rescreened
IV-12 30/F 56 (99) 58 N NSST
37/F 51 (97.5) 60 N NSST
V-3 24/F 54 (99) 60 N none
31/F 54 (99) 55 N none
Percentiles are derived from gender- and height-based standards (see Methods); percentiles are shown only if equal to or greater than the 95th percentile.
1st deg AVB  first-degree atrioventricular block; DCM  dilated cardiomyopathy (LVE  systolic dysfunction); LBBB  left bundle branch block; N/A  data not
available; NSST  nonspecific ST-T wave abnormalities; NYHA  New York Heart Association; PVC  premature ventricular contraction.
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